Resultados de la búsqueda 81-90 of 21505 for Treatment
ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). ... treatment and may reduce the burden of cancer and ...
-Collect data, images, from patients undergoing surgical treatment of hip disorders (we will not be collecting social security numbers to send to Washington ...
... treatment, post-treatment and (when available) post-mortem soft tissue sarcoma (STS) tissue and tissue data with an emphasis on STSs occurring in younger ...
ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). ... treatment, post-treatment and (when available) post ...
ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...
... treatment (refractory). Testing The Addition Of Abemaciclib To Olaparib For Women With Recurrent Ovarian Cancer. Jacksonville, Fla., Rochester, Minn ...
Treatment options are then defined according to the disease burden strata. Treatment is allocated by randomisation. Patients may be allocated to one of ...
... treatment in patients with recurrent grade 2 or 3 meningioma as measured by ... treatment, post-treatment and (when available) post-mortem soft tissue ...
... treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this ...
Patients may receive a single dose to a liver lobe or segmental treatment delivered as a sequence of treatments approximately 30-90 days apart. The ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?